DMB-I in the Treatment of Alzheimer Type Dementia

This is a multicenter, randomized, placebo-controlled study that is to assess efficacy and safety, to select the optimal therapeutic dose of the drug and to test the hypothesis of superiority of DMB-I (Dimebon) over placebo in patients with mild to moderate Alzheimer's disease. The study is planned to be conducted in clinical sites of the Russian Federation. Patients meeting all the eligibility criteria will be randomized into one of three treatment arms: 1. DMB-I (Dimebon) 1 tab + Placebo 1 tab 3 times a day. 2. DMB-I (Dimebon) 2 tab 3 times a day. 3. Placebo 2 tab 3 times a day. The total study duration for each patient is approximately 182 days broken down as follows: Screening period: up to 14 days, Treatment period: 26 weeks, Follow-up period: 2 weeks.